- Targets
- 5
- Filings
- 10
- Median premium
- 40%
- First filing
- Jan 22, 2020
- Latest filing
- Aug 10, 2026
Targets
| Company | Score before deal | Score now | Filings | Latest |
|---|---|---|---|---|
| AtaiBeckley Inc. | — | — | 3 | Aug 10, 2026 |
| Centessa Pharmaceuticals plc | — | — | 2 | May 7, 2026 |
| Ventyx Biosciences, Inc. | — | — | 3 | Feb 2, 2026 |
| Prevail Therapeutics Inc. | — | — | 1 | Dec 22, 2020 |
| Dermira, Inc. | — | — | 1 | Jan 22, 2020 |
Deal filings
| Filed | Company | Form | Price | Premium |
|---|---|---|---|---|
| Aug 10, 2026 | AtaiBeckley Inc. | DEFM14A | $6.75 | 40% |
| Jul 30, 2026 | AtaiBeckley Inc. | PREM14A | $6.75 | 40% |
| Jul 16, 2026 | AtaiBeckley Inc. | 8-K | — | — |
| May 7, 2026 | Centessa Pharmaceuticals plc | DEFM14A | $38.00 | 40% |
| Apr 17, 2026 | Centessa Pharmaceuticals plc | PREM14A | $38.00 | 40% |
| Feb 2, 2026 | Ventyx Biosciences, Inc. | DEFM14A | $14.00 | 62% |
| Jan 22, 2026 | Ventyx Biosciences, Inc. | PREM14A | $14.00 | 62% |
| Jan 7, 2026 | Ventyx Biosciences, Inc. | 8-K | — | — |
| Dec 22, 2020 | Prevail Therapeutics Inc. | SC TO-T | — | — |
| Jan 22, 2020 | Dermira, Inc. | SC TO-T | — | — |